Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Epigenetic Therapeutics to Overcome Resistance Against Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A Proof-of-concept Clinical Trial

NCT05873244 is registered in ClinicalTrials.gov with Stephen Chan Lam as lead sponsor.

NCT NCT05873244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05873244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Epigenetic Therapeutics to Overcome Resistance Against Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A Proof-of-concept Clinical Trial
Lead sponsor
Stephen Chan Lam
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 21, 2023
Completion date
December 30, 2028
Enrollment
26 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hcc